A CETP inhibitor duo and a next-generation PCSK9 therapy are a step closer to gaining EU approval as new cholesterol-lowering medicines.
A CETP inhibitor duo and a next-generation PCSK9 therapy are a step closer to gaining EU approval as new cholesterol-lowering medicines.